Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,831 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06497387RecruitingEarly Phase 1
PRG-1801 for stubborn lupus kidney and IgG4 disease
This trial tests a new treatment called PRG-1801 for people with lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that has not improved with standard treatments. The treatment uses your own immune cells to target and calm the disease.
Wuhan, HubeiAges 18 years+ - NCT06498089RecruitingPhase 4
Comparing tailored vs. standard treatment for active Takayasu's arteritis.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06499233RecruitingPhase 4
Study on preventing pneumocystis pneumonia in autoimmune disease
This trial tests whether a preventive treatment can stop pneumocystis pneumonia (a lung infection) in people with autoimmune inflammatory rheumatic diseases who are taking steroids or other immune-suppressing medicines. It aims to find the safest and most effective way to protect you from this serious infection.
Wuhan, HubeiAges 18 years+ - NCT06503237Recruiting
SWK002 for tough-to-treat rheumatoid arthritis
This trial tests a new treatment called SWK002 for people with rheumatoid arthritis that hasn't improved after trying multiple medications. It aims to see if SWK002 can help when other treatments have failed.
Changsha, HunanAges 18 years+ - NCT06503809Recruiting
Ketogenic diet study for type 1 diabetes
This study tests if a very low-carb (ketogenic) diet is safe and helps control blood sugar in people with type 1 diabetes. You would follow the diet for a period and use a continuous glucose monitor to track your levels.
St Louis, MissouriAges 18–65 - NCT06507683Recruiting
Radiation plus ripretinib for advanced GIST
This trial tests whether adding radiation therapy to the drug ripretinib can help people with advanced gastrointestinal stromal tumors (GIST) that can't be removed by surgery and have stopped responding to other treatments. It aims to see if this combination is safe and effective.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06508931RecruitingPhase 2
Zamtocabtagene autoleucel for children with B-cell lymphoma or leukemia
This trial tests a new CAR T-cell therapy (zamtocabtagene autoleucel) for children and teens whose B-cell lymphoma or leukemia has come back or hasn't responded to other treatments. The goal is to see if this one-time infusion can help their immune system fight the cancer.
Paris, Boulevard Sérurier 48Ages 6 months–17 years - NCT06510283RecruitingPhase 2
Taitacept for refractory or recurrent autoimmune encephalitis
This trial tests a new drug called Taitacept for people with autoimmune encephalitis (brain inflammation caused by the immune system) that has not improved with standard treatments or has returned. The goal is to see if Taitacept can help control symptoms.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06512584RecruitingPhase 3
Study of PJ009 for short bowel syndrome patients needing IV nutrition
This trial tests a new medicine called PJ009 for people with short bowel syndrome who need intravenous (IV) nutrition support. It aims to help reduce the need for IV nutrition. To join, you must have been dependent on IV nutrition for at least six months and be on a stable schedule.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06514469Recruiting
Painkiller (sufentanil) given by paramedics for severe trauma pain
This trial tests whether paramedics can safely give a strong painkiller (sufentanil) to adults with severe pain from a recent injury. It aims to see if it works well and is safe when given in the field.
Karlovy Vary, Karlovy Vary RegionAges 18 years+ - NCT06515015Recruiting
Trial of a plug for air leaks that won't heal after chest tube drainage
This trial tests a new silicone plug placed through a bronchoscope to stop air leaks in patients whose pneumothorax hasn't healed after a week of chest tube drainage. It aims to see if the plug is safe and works as a treatment for this condition.
Quanzhou, FujianAges 18 years+ - NCT06515132Recruiting
Spinal cord stimulation for consciousness after brain injury
This trial tests whether spinal cord stimulation can help people who have been minimally conscious for months after a brain injury. It aims to improve awareness and responsiveness by using mild electrical pulses.
Fuzhou, FujianAges 18–65 - NCT06515262Recruiting
Testing anti-BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Kunming, Kunming, YunnanAges 18–75 - NCT06518005RecruitingPhase 2
Gene therapy for severe Crigler-Najjar syndrome
This trial tests a new gene therapy called GNT0003, given after a pre-treatment to help it work, for people with severe Crigler-Najjar syndrome. The goal is to see if it can reduce the need for daily light treatments.
ClamartAges 18 years+ - NCT06519565RecruitingEarly Phase 1
Testing PRG-1801 for hard-to-treat immune thrombocytopenia
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
Wuhan, HubeiAges 18 years+ - NCT06520410RecruitingPhase 4
Short vitrectomy tool for children's eye surgery
This trial tests a shorter, 18-millimeter tool for vitrectomy surgery in children. It aims to see if this smaller tool is safe and works well for treating various eye problems in kids.
TaoyuanAges birth–18 years - NCT06520397RecruitingPhase 4
Combination therapy vs. higher dose ustekinumab for Crohn's
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
Guangzhou, GuangdongAges 18–70 - NCT06522555RecruitingPhase 3
Testing Pola-ZR2 vs ZR2 for older adults with lymphoma
This trial tests a new combination of drugs (Pola-ZR2) against a standard combination (ZR2) for older adults with newly diagnosed diffuse large B-cell lymphoma. It aims to see if the new mix is more effective and safe.
ShanghaiAges 70 years+ - NCT06523400RecruitingPhase 3
Mexiletine for myotonic dystrophy types 1 and 2
This trial tests a once-daily drug called mexiletine PR to see if it can help reduce muscle stiffness (myotonia) in people with myotonic dystrophy type 1 or 2. It may be a good option if you have a confirmed genetic diagnosis and are at least 16 years old.
LeuvenAges 16 years+ - NCT06528405RecruitingPhase 2
SGLT2 inhibitor study for acute kidney disease patients
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
TaipeiAges 18–80 - NCT06528444RecruitingPhase 3
Dexamethasone vs placebo for severe flu patients
This trial tests whether dexamethasone (a steroid) can help people hospitalized with severe flu recover faster. It is for adults who are already taking Tamiflu and do not have other serious infections like COVID-19.
AlicanteAges 18–100 - NCT06531707RecruitingPhase 3
Ibuprofen and loratadine for cold symptoms
This trial tests whether taking ibuprofen (a pain reliever) together with loratadine (an allergy medicine) works better than either medicine alone for common cold symptoms like sneezing, runny nose, headache, and cough. It may help you feel better faster.
Mexico CityAges 18 years+ - NCT06532058RecruitingPhase 2
Study of a new drug for relapsed or hard-to-treat acute myeloid leukemia
This trial tests an experimental drug called QHRD107 combined with other medicines for people whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The goal is to see if the new combination is safe and helps control the leukemia.
Zhengzhou, HenanAges 18 years+ - NCT06532643RecruitingEarly Phase 1
CAR-T cells targeting CD20 and CD30 for relapsed lymphoma
This trial tests a new CAR-T cell therapy that targets two proteins (CD20 and CD30) on lymphoma cells. It is for people whose lymphoma has come back or not responded to other treatments, including previous stem cell transplants. The goal is to see if this treatment is safe and helps shrink or control the lymphoma.
Hefei, AnhuiAges 14–70
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,831 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.